(Q34086049)

English

Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies (English)

1 reference

Europe PubMed Central

30 July 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

C R Culy

1

1 reference

Europe PubMed Central

30 July 2017

D Clemett

2

1 reference

Europe PubMed Central

30 July 2017

L R Wiseman

3

1 reference

Europe PubMed Central

30 July 2017

publication date

1 October 2000

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

60

1 reference

Europe PubMed Central

30 July 2017

895-924

1 reference

Europe PubMed Central

30 July 2017

4

1 reference

Europe PubMed Central

30 July 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200060040-00005

0 references

Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative adverse effect profiles of platinum drugs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors influencing the natural history of colorectal liver metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specificity of platinum–DNA adduct repair

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin/carboplatin cross-resistance in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin: a review of its use in the management of metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracellular glutathione and cytotoxicity of platinum complexes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of oxaliplatin against human tumor colony-forming units.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of oxaliplatin: a critical review

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of l-OHP in mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronothe

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Where do we stand with 5-fluorouracil?

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin: pharmacokinetics and chronopharmacological aspects

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy of advanced ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anaphylaxis after oxaliplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin: mechanism of action and antineoplastic activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Severe anaphylactic reactions to oxaliplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin in practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of refractory and recurrent ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of DNA mismatch repair in platinum drug resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumour activity of oxaliplatin in neuroblastoma cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11085200

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200060040-00005

1 reference

Europe PubMed Central

30 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34086049&oldid=1970781402"